Fanconi anemia (FA) is an autosomal recessive disease which manifests increased risk of leukemia, regressive bone marrow failure, skeletal abnormalities, altered skin pigmentation and developmental delay. Therefore FA presents alterations in growth and development with anemia, and is an autosomal recessive disease with increased risk of cancer. There are eight complementation groups identified, indicating the involvement of multiple genes in the disease. This Program Project will use a molecular genetic approach to define the genetic elements causing Fanconi anemia and the function of the gene products in order to improve diagnosis and treatment. The concept of this project is to take a multi-disciplinary approach to the definition of the causes of Fanconi anemia at the molecular and cellular level. The clinical disciplines represented by the Investigators include medicine, pediatrics, medical genetics, hematology and oncology. The scientific areas of the investigations include molecular hematology, molecular genetics, mouse genetics, gene therapy, stem cell biology and DNA repair. The proposed project will have three investigative components and three core components: Project 1 will participate in cloning the FA-D group gene and analyze the function of the FA-D protein. Pathogenesis of FA as a result of crosslink repair defects will be tested in mouse models. Project 2 will participate in cloning FA-D and will build mouse models deficient in FA-D and FA-A gene products. Project3 will asess the apoptotic cytokine response defects in FA and define the molecular hematological defects in the mouse models. The Cytogenetics Core will test chromosome breakage in new Fanconi anemia cell line candidates and help map candidate Fanconi anemia genes. The Fanconi Anemia Cell Repository will identify Fanconi anemia cell lines for complementation testing and establish permanent cell lines for investigators as well as provide diagnostic procedures for FA patients and their providers.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL048546-07
Application #
6183091
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
1994-07-01
Project End
2004-06-30
Budget Start
2000-08-01
Budget End
2001-06-30
Support Year
7
Fiscal Year
2000
Total Cost
$1,598,800
Indirect Cost
Name
Oregon Health and Science University
Department
Genetics
Type
Schools of Medicine
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Whiteaker, Jeffrey R; Zhao, Lei; Ivey, Richard G et al. (2018) Targeted mass spectrometry enables robust quantification of FANCD2 mono-ubiquitination in response to DNA damage. DNA Repair (Amst) 65:47-53
Mouw, Kent W; Goldberg, Michael S; Konstantinopoulos, Panagiotis A et al. (2017) DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov 7:675-693
Kroeger Jr, Paul T; Drummond, Bridgette E; Miceli, Rachel et al. (2017) The zebrafish kidney mutant zeppelin reveals that brca2/fancd1 is essential for pronephros development. Dev Biol 428:148-163
Rondinelli, Beatrice; Gogola, Ewa; YĆ¼cel, Hatice et al. (2017) EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol 19:1371-1378
Karras, Georgios I; Yi, Song; Sahni, Nidhi et al. (2017) HSP90 Shapes the Consequences of Human Genetic Variation. Cell 168:856-866.e12
Garbati, Michael R; Hays, Laura E; Rathbun, R Keaney et al. (2016) Cytokine overproduction and crosslinker hypersensitivity are unlinked in Fanconi anemia macrophages. J Leukoc Biol 99:455-65
Zhang, Qing-Shuo; Tang, Weiliang; Deater, Matthew et al. (2016) Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice. Blood 128:2774-2784
Zhang, Haojian; Kozono, David E; O'Connor, Kevin W et al. (2016) TGF-? Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. Cell Stem Cell 18:668-81
Zhang, Qing-Shuo; Benedetti, Eric; Deater, Matthew et al. (2015) Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic stem cell cycling. Stem Cell Reports 4:90-102
Lombardi, Anne J; Hoskins, Elizabeth E; Foglesong, Grant D et al. (2015) Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers. Clin Cancer Res 21:1962-72

Showing the most recent 10 out of 106 publications